Mon, Aug 22, 2016
Pfizer Inc has agreed to buy Medivation Inc which is a biopharmaceutical company focused on developing and commercializing in the treatment for cancer. The merger will be for $81.50 a share in cash for a total enterprise value of approximately $14 billion.
More >
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.